Signaling pathway profiling using reverse-phase protein array and its clinical applications.

Area of Science:

• Oncology
• Proteomics
• Genomics

Background:

• Next-generation sequencing has advanced cancer treatment towards precision medicine.
• Current genomic and transcriptomic approaches have limitations in predicting protein expression and modifications.
• Durable efficacy in cancer treatment remains a challenge.

Purpose of the Study:

• To review advances in precision medicine.
• To highlight the utility of antibody-based reverse-phase protein array (RPPA) technology in precision medicine.
• To underscore the need for proteomic analysis in cancer treatment.

Main Methods:

• Review of recent advances in precision medicine.
• Discussion of antibody-based reverse-phase protein array (RPPA) technology.
• Analysis of RPPA's suitability for pharmacodynamics and clinical applications.

Main Results:

• Genomic approaches alone are insufficient for fully personalized cancer therapy.
• RPPA technology enables precise mapping of signaling status using limited clinical samples.
• RPPA is cost-effective and offers rapid turnaround time compared to other molecular profiling technologies.

Conclusions:

• Proteomic analysis, particularly RPPA, is crucial for the next stage of precision medicine.
• RPPA is well-suited for pharmacodynamics analysis in clinical settings.
• The advantages of RPPA make it a valuable tool for advancing personalized cancer treatment.